Latest news and insights on the pharmaceutical industry | Indian Pharma Post

Results For "Fudan-University-Shanghai-Cancer-Center"

2 News Found

ENHERTU approved in China as first HER2-targeted ADC for early breast cancer
Drug Approval | March 31, 2026

ENHERTU approved in China as first HER2-targeted ADC for early breast cancer

The decision is based on the phase 3 DESTINY-Breast11 trial


ENHERTU gains first-ever nod in China for metastatic breast cancer
Drug Approval | December 29, 2025

ENHERTU gains first-ever nod in China for metastatic breast cancer

The approval follows results from the DESTINY-Breast06 phase 3 trial, which showed ENHERTU significantly extended progression-free survival compared to chemotherapy